Related by context. All words. (Click for frequent words.) 77 EDSS scores 74 MADRS score 72 Expanded Disability Status 72 EDSS 72 HbA 1c levels 71 Hb A1C 71 MMSE score 71 Scale EDSS 71 NIHSS 71 CDAI score 70 NYHA functional class 70 mRS 69 HbA 1c 69 PASI scores 69 DAS# [002] 69 baseline HbA1c 69 Scale EDSS score 69 Ishak fibrosis score 69 definite stent thrombosis 69 hemoglobin A1c levels 68 Index CDAI 68 MMSE scores 68 virological response 68 NIHSS score 68 HAQ DI 68 ACR Pedi 68 macroalbuminuria 67 Crohn Disease Activity 67 pCR 67 PSADT 67 annualized relapse 67 ACR# response 67 NIH CPSI 67 % CI #.#-#.# [007] 67 HbA1C levels 67 CCyR 67 complete cytogenetic response 67 recurrent VTE 67 lumbar spine BMD 66 SUVmax 66 Score DAS# 66 mg kg dose 66 hours postdose 66 LVEF 66 alanine aminotransferase ALT 66 NYHA class 66 anemia hemoglobin 66 clinically meaningful improvement 66 T2 lesions 66 adjunctive placebo 66 QTcF 66 mTSS 66 antibody titer 66 PSA nadir 66 evaluable subjects 66 timepoints 66 Timed Walk 66 X ULN 66 atheroma volume 66 CR nPR 66 dosing cohort 65 NNT = 65 virologic response 65 mL/min/#.# m 2 65 glycated hemoglobin levels 65 IBDQ 65 methotrexate monotherapy 65 Y BOCS 65 adefovir treated 65 Postoperatively 65 HDRS 65 achieved ACR# 65 DAS# CRP 65 albumin excretion 65 postintervention 65 biochemical relapse 65 log# reduction 65 Operative mortality 65 COPAXONE R 65 biochemical recurrence 65 CDAI 65 hip BMD 65 serum HCV RNA 65 MetS 65 severe exacerbations 65 A1c levels 65 CIN3 65 #.#ng/ml 65 radiographic progression 65 serum aminotransferase levels 65 nondiabetic patients 65 moderate renal impairment 64 ADAS cog 64 eGFR 64 liver histology 64 corticosteroid dose 64 serum urate 64 UPDRS 64 p = #.# [003] 64 % Confidence Interval 64 % CI #.#-#.# [003] 64 HbA1c levels 64 IRLS score 64 HAM D# scores 64 hematologic toxicity 64 perioperative mortality 64 femoral neck BMD 64 CrCl 64 seroprotection 64 Index CDAI score 64 leukocyte count 64 baseline FEV 64 aged ≥ 64 systolic dysfunction 64 mean baseline HbA1c 64 estimated glomerular filtration 64 preoperative PSA 64 apnea hypopnea index 64 DAS# remission 64 CI #.#-#.# [001] 64 mg/m2 dose 63 lopinavir r arm 63 morphometric vertebral fractures 63 HBeAg seroconversion 63 timepoint 63 estimated GFR 63 plasma cortisol 63 neutrophil counts 63 postoperative mortality 63 Hb A1c 63 tipranavir r 63 Health Assessment Questionnaire 63 serum IGF 63 p = .# [001] 63 IFN beta 63 microalbuminuria 63 baseline A1C 63 serum testosterone 63 serum phosphate 63 serum phosphate levels 63 SGRQ 63 % CI #.#-#.# [006] 63 CI -#.# 63 nonobese 63 alteplase 63 plasma HCV RNA 63 SELENA SLEDAI score 63 ALT elevation 63 serum clusterin levels 63 μg dL 63 levodopa therapy 63 PREZISTA r arm 63 relapsed MM 63 certolizumab 63 albumin excretion rate 63 mIU L 63 adenoma recurrence 63 Platelet counts 63 Ejection Fraction 63 Unified Parkinson Disease 63 virological failure 63 hemoglobin A1c HbA1c 62 Brief Psychiatric 62 elevated LDH 62 oxycodone CR 62 titration phase 62 6MWD 62 DLQI 62 fasting triglyceride levels 62 baseline LDH 62 R0 resection 62 KRAS mutations occur 62 virologic failure 62 -#.# log# 62 mmHg diastolic 62 CIMZIA TM 62 glomerular filtration 62 posttreatment 62 aspartate aminotransferase AST 62 preintervention 62 MACCE 62 PANSS total 62 cytogenetic response 62 interquartile range 62 urine albumin 62 undetectable HBV DNA 62 tapentadol ER 62 % CI #.#-#.# [004] 62 mg BID dose 62 calculated creatinine clearance 62 COPD exacerbation 62 REYATAZ r arm 62 preoperative chemotherapy 62 sUA 62 #mg/day [001] 62 aminotransferases 62 subscore 62 intraobserver 62 octreotide LAR 62 nonfasting triglyceride levels 62 Kaplan Meier analysis 62 HRQoL 62 ALT flares 62 nondepressed 62 T2DM 62 BPH Symptom Score 62 lymphocytosis 62 elevated ALT 62 binary restenosis 62 serum creatinine levels 62 Montgomery Asberg Depression 62 5-FU/LV 62 femoral shaft fracture 62 Baseline characteristics 62 recurrent wheezing 62 μmol L 62 hepatitis C genotype 62 amoxicillin clavulanate 62 partial remissions 62 peak VO2 62 statistical significance p 62 YMRS 62 Psoriasis Area 62 RECIST criteria 62 baseline FEV1 62 gadolinium enhancing lesions 62 HSCT 62 transaminase levels 62 Response Evaluation Criteria 62 SCr 62 FOLFOX4 62 Solid Tumors criteria 62 splenectomized patients 62 experienced virologic failure 62 ml kg 62 FluCAM 62 biopsy Gleason 62 clinically meaningful improvements 62 p = .# [002] 62 rimonabant #mg 61 advanced adenomas 61 detectable HCV RNA 61 ejection fractions 61 myocardial reperfusion 61 advanced adenoma 61 UPDRS scores 61 Disease Activity 61 adjunctive ABILIFY 61 receiving golimumab 61 mean baseline A1C 61 asthma exacerbation 61 spirometric 61 CIMZIA ™ 61 Montgomery Åsberg Depression 61 CNS LS 61 WOMAC pain 61 troponin T 61 beta blocker therapy 61 HbA1C 61 LS BMD 61 asymptomatic carotid stenosis 61 complete cytogenetic 61 serologically active patients 61 CsA 61 serum HBV DNA 61 8mg/kg 61 GnRH agonist 61 HRQL 61 OGTT 61 hepatorenal syndrome 61 postoperative complication 61 Severity Index PASI 61 ACR# responses 61 median PFS 61 retinal thickness 61 depressive symptomatology 61 mcg Albuferon 61 pulmonary exacerbations 61 arterial thromboembolic events 61 hydroxyvitamin D levels 61 uncorrected visual acuity 61 sd = 61 #mg dose [002] 61 prospectively defined 61 DMARD 61 genotypic resistance 61 inotropic 61 oral allopurinol 61 P = .# 61 hip resurfacing arthroplasty 61 NPH insulin 61 symptom severity 61 glycated hemoglobin HbA1c 61 ng dL 61 methotrexate therapy 61 SCIg 61 placebo dexamethasone 61 nonvertebral fractures 61 urinary albumin excretion 61 ETDRS 61 transaminase elevations 61 fluticasone salmeterol 61 QRS duration 61 CPAP adherence 61 MCyR 61 g dl 61 prospectively stratified 61 β blockers 61 mmol l 61 confidence intervals CIs 61 creatinine clearance 61 ipsilateral stroke 61 atazanavir ritonavir 61 lymphocyte count 61 ± SD 61 colorectal adenoma 61 symptom exacerbation 61 CORE OM 61 low dose cytarabine 61 neurodevelopmental impairment 61 IOP lowering 61 tuberculin skin testing 61 logistic regression model 61 RLAI 61 dopamine partial agonist 61 CR CRu 61 tertiles 61 microg 60 plasma glucose concentrations 60 hemoglobin concentration 60 preoperatively 60 #mmHg [001] 60 foveal thickness 60 specific antigen PSA 60 Hb levels 60 mcg albinterferon alfa 2b 60 salmeterol fluticasone propionate 60 peginterferon alfa 2a 60 plus methotrexate 60 pelvic lymphadenectomy 60 AUA BPH Symptom Score 60 mL/min/#.# m2 60 creatinine ratio 60 alanine aminotransferase 60 BMI z 60 thyrotropin levels 60 hemoglobin Hb 60 ADCS ADL 60 receiving Vectibix monotherapy 60 x ULN 60 left ventricular systolic 60 HOMA IR 60 adalimumab 60 carotid IMT 60 intima media thickness 60 urate lowering therapy 60 paraprotein 60 DAS# scores 60 Betaferon ® 60 nocturnal awakenings 60 Rating Scale MADRS 60 per deciliter mg 60 Hazard Ratio 60 Postoperative complications 60 blood Phe levels 60 DMARD therapy 60 mEq L 60 QTc 60 glomerular filtration rate 60 laboratory abnormalities 60 sustained virological response 60 chlorambucil 60 Kaplan Meier estimate 60 IU ml 60 hepatic enzymes 60 TEAEs 60 FOLPI 60 HBV DNA 60 nonoperative treatment 60 NATRECOR R 60 response CCyR 60 secondary efficacy endpoint 60 APTIVUS r 60 sUA levels 60 #mg BID [001] 60 UPDRS motor 60 weekly CSBMs 60 atorvastatin #mg 60 CHD mortality 60 % CI #.#-#.# [008] 60 divalproex sodium 60 #.#/#.# mmHg [001] 60 tolvaptan 60 ARB telmisartan 60 elevated serum creatinine 60 mcg BID 60 ug kg 60 hippocampal volumes 60 pT3 60 carotid stenosis 60 serum ferritin 60 antibody titers 60 statistically significant p = 60 seropositivity 60 subclinical hyperthyroidism 60 moderately emetogenic 60 IFN α 60 adenotonsillectomy 60 hsCRP levels 60 HI titers 60 airflow obstruction 60 fragility fracture 60 Case persistency 60 intramuscular dose 60 mesalamine granules 60 pmol L 60 IPSS 60 tertile 60 nonpregnant women 60 STN stimulation 60 serum potassium 60 serum uric acid 60 chronic periodontitis 60 univariate analysis 60 paroxysmal AF 60 attain statistical significance 60 % CI #.#-#.# [005] 60 desvenlafaxine succinate 60 generalized edema 60 placebo p = 60 pg mL 60 underwent resection 60 neostigmine 60 advanced neoplasia 60 fasting plasma glucose FPG 60 CLA supplementation 60 CVD mortality 60 univariate analyzes 60 IFN alfa 60 blastic phase 60 -#.# ± [002] 60 prevalences 60 isolated systolic hypertension 60 ADHD RS 60 affective psychosis 60 mIU ml 60 HER2 expression 60 Solid Tumors RECIST 60 glycated hemoglobin 60 Kaplan Meier estimates 60 nonobstructive CAD 60 salmeterol fluticasone 60 DLTs 60 overt nephropathy 60 baseline PASI 59 aminotransferase elevations greater 59 ximelagatran 59 mcg dose 59 μg L 59 confidence interval CI 59 hypogonadal men 59 remission CR 59 insulin detemir 59 BPRS PSS 59 subtrochanteric 59 ertapenem 59 dyspnoea 59 mg BID 59 4mg/kg 59 serum ALT 59 autonomic dysfunction 59 oral anticoagulation 59 XIENCE V PROMUS Stent 59 subsyndromal 59 postprocedure 59 TNF antagonist 59 subclinical hypothyroidism 59 IV NSCLC 59 endoscopic remission 59 RSV hospitalizations 59 serum cortisol 59 invasive aspergillosis 59 acromegalic patients 59 neurologic impairment 59 oral FTY# 59 microbiological eradication 59 venlafaxine XR 59 atrophic gastritis 59 serum lipid levels 59 FDG uptake 59 NNRTI resistance 59 PANSS 59 mcg QD 59 gout flares 59 endometrial thickness 59 achieving PASI 59 WOMAC 59 elevated troponin 59 PCWP 59 elevated triglyceride levels 59 low dose Iluvien 59 dose cohort 59 serum calcium levels 59 CSBMs 59 poststroke 59 μg liter 59 platelet inhibition 59 PegIFN RBV 59 arterial thickening 59 dysthymia 59 lowest tertile 59 clodronate 59 alemtuzumab treated 59 hour bronchodilation 59 ACR# [002] 59 glycosylated hemoglobin HbA1c 59 Free Survival PFS 59 hippocampal atrophy 59 femoral neck fracture 59 PREZISTA r 59 squamous histology 59 Insulin sensitivity 59 NYHA 59 fasting insulin 59 pg ml 59 IR prednisone 59 BENICAR HCT 59 ALND 59 postdischarge 59 LV hypertrophy 59 p = NS 59 serum concentrations 59 ZOMIG Nasal Spray 59 daunorubicin 59 abatacept 59 autoantibody positive 59 Serum creatinine 59 rapid virological response 59 coronary calcification 59 FDA defined valvulopathy 59 TMC# r 59 iPTH 59 BMI ≥ 59 cTnT levels 59 EQ 5D 59 normal ULN 59 sleeve lobectomy 59 Natalizumab 59 pulmonary dysfunction 59 6MW distance 59 RECIST 59 FFNS 59 ADAS Cog 59 APACHE II 59 intravenous diuretics 59 virologic response EVR 59 tiotropium 59 psychiatric comorbidities 59 biologic DMARD 59 WOMAC scores 59 #.#mg/dL 59 histologically confirmed 59 â ‰ ¥ 59 pmol liter 59 TKAs 59 psychiatric comorbidity 59 hemoglobin concentrations 59 antihypertensive therapy 59 Hemoglobin A1c HbA1c 59 6MWT 59 nonvertebral fracture 59 mmHg systolic 59 coronary revascularization 59 Rating Scale BPRS 59 ADCS CGIC 59 CD4 + cell 59 periprocedural 59 primary patency 59 umol L 59 poor metabolizers 59 T2 lesion volume 59 VO2 peak 59 resected pancreatic cancer 59 serum testosterone levels 59 Non inferiority 59 nasal symptom 59 Lumbar spine 59 logistic regression analysis 59 chemoradiation therapy 59 mL kg 59 aminotransferase levels 59 achieved CCyR 59 dosing cohorts 59 postoperatively 59 HbA 1C 59 HbA1c 59 titrated glipizide 59 care regimens CCR 59 ACTEMRA TM 59 MMSE 59 hypoperfusion 59 sensory neuropathy 59 extrapyramidal symptoms 59 serum urate levels 59 mL sec 59 systemic corticosteroid 59 plain radiographs 59 Adjuvant chemotherapy 59 polyp recurrence 59 nonfatal MI 59 lymphadenectomy 59 intravitreal injections 59 Breslow thickness 59 concomitant AEDs 59 symptomatic GERD 59 antihypertensive medication 59 Status Scale EDSS 58 Visual acuity 58 PRADAXA #mg 58 pulmonary exacerbation 58 sustained virologic response 58 relapsing MS 58 Alzheimer Disease Assessment 58 mU L 58 expiratory flow 58 FAMPYRA 58 Negative Syndrome 58 infarcts 58 follicular lymphomas 58 azacitidine 58 serum PSA 58 ARIXTRA 58 #OHD 58 multivariate analyzes 58 DCCT 58 NMIBC 58 HGPIN 58 ml min 58 UACR 58 mcg mL 58 depressive symptom 58 Knodell necroinflammatory score 58 microalbumin test 58 ≥ 58 mRCC 58 Skin sterol 58 Viral load 58 non hematological toxicities 58 RRMS patients 58 RECIST Response Evaluation Criteria 58 Viread Emtriva Sustiva 58 eplerenone 58 RESIST studies 58 -#.# mg dL [002] 58 oncologic outcomes 58 INVEGA ® 58 tacrolimus ointment 58 abnormal p# biomarker 58 serum folate 58 ECOG PS 58 multivariable analysis 58 nephrectomy 58 multivariable analyzes 58 nmol l 58 ischemic lesions 58 micrograms mL 58 fraction LVEF 58 pulmonary capillary wedge 58 sham injections 58 infliximab monotherapy 58 interobserver reliability 58 iniparib BSI 58 mucosal healing 58 undetectable viral load 58 HBeAg negative patients 58 radical nephrectomy 58 AVODART 58 KRAS mutant tumors 58 logistic regression models 58 prednisone prednisolone 58 arterial oxygen saturation 58 ICD therapy 58 intermittent claudication 58 log# copies mL 58 mg/m2/day 58 #Gy 58 hemagglutination inhibition 58 ARCOXIA 58 dopaminergic therapy 58 extracolonic findings 58 CTEPH 58 symptomatic intracerebral hemorrhage 58 SLNB 58 Score DAS 58 Primary endpoints 58 IU mL 58 HPA axis suppression 58 perioperative complications 58 thyroglobulin 58 creatinine levels 58 Doxil ® 58 Retreatment 58 NHANES III 58 blood Phe 58 GH deficiency 58 locoregional disease 58 ICD implantation 58 diabetes mellitus DM 58 angiographic restenosis 58 maximal treadmill 58 aspartate aminotransferase 58 mmol L. 58 CRp 58 maximal aerobic capacity 58 serum phosphorous 58 coronary stenosis 58 CYPHER Stent 58 pneumonectomy 58 OAB symptoms 58 serum phosphorus 58 colectomy 58 Stent thrombosis 58 erythrocyte sedimentation rate 58 hemodialysis patients 58 revascularizations 58 LEXIVA r 58 prespecified secondary 58 subscale scores 58 hypoglycemic episodes 58 potent antiretroviral therapy 58 onset diabetes mellitus 58 XEPLION R 58 CLBP 58 HBeAg 58 imipenem 58 intravaginal ejaculatory latency 58 serum creatinine 58 Thrombolysis 58 Bonferroni correction 58 baseline Hb 58 thromboprophylaxis 58 CANCIDAS 58 highly emetogenic 58 STRIDE PD 58 serum PTH 58 μg kg 58 CHOP chemotherapy 58 platelet reactivity 58 haematologic 58 Median PFS 58 histologically 58 systemic corticosteroids 58 HIV uninfected 58 viral titers 58 spontaneous bowel movements 58 MoxDuo TM IR 58 Prehypertension 58 SSRI SNRI 58 antihypertensive medications 58 atrioventricular block 58 dosage regimens 58 mm Hg systolic 58 diastolic hypertension 58 doxorubicin docetaxel 58 del 5q MDS 58 metformin monotherapy 58 T1DM 58 severe periodontitis 58 plus MTX 58 underwent CABG 58 PASI score 58 dose clopidogrel 58 Subgroup analysis 58 comparator arm 58 ug mL 58 mCRC patients 58 ziprasidone 58 mg ustekinumab 58 fasting glucose levels 58 NLX P# 58 odds ratios ORs 58 non menstrual pelvic 58 TAVR 58 bronchial hyperresponsiveness 58 corrected QT interval 58 death reinfarction 58 HRQOL 58 nodular partial response 58 histologic subtype 58 rectal bleeding subscore 58 Flu Cy 58 sinus bradycardia 58 receiving ISENTRESS 58 atherogenic dyslipidemia 58 prodromal symptoms 58 anagrelide 58 free survival PFS 58 non squamous NSCLC 58 Folfox 58 International Prostate Symptom 58 progression TTP 58 logistic regression analyzes 58 HAART regimen 58 dalteparin 58 severe renal impairment 58 posttransplant 58 Tumor shrinkage 58 recurrent venous thromboembolism 58 urinary N telopeptide 58 urinary calcium excretion 58 histological subtype 58 Median survival 58 cytogenetic responses 58 nadroparin 58 Multivariate analysis 58 CIMZIA TM certolizumab pegol 58 acetabular dysplasia 58 neurologic dysfunction 58 dapagliflozin plus 58 plasma glucose concentration 58 oxygen desaturation 58 incontinence episodes 58 mcg ml 58 Perforomist Inhalation Solution 58 FEV1 58 eculizumab therapy 58 prognostic variables 58 mg dose 57 reperfusion therapy 57 pT2 57 SRBD 57 AGILECT R 57 Fasting blood glucose 57 aPTT 57 hypertensives 57 DAPT 57 flutamide 57 bosentan 57 EBRT 57 LV dysfunction 57 clinically localized prostate 57 pramipexole 57 perioperative morbidity 57 mg QD 57 mCi m 2 57 chronic GVHD 57 p = #.# [002] 57 androgen deprivation 57 fosamprenavir 57 episodic migraine 57 systolic BP 57 mg Proellex 57 lower extremity amputation 57 HIV HCV coinfected 57 XELOX 57 rebleeding 57 IELT 57 PANSS scores 57 acute gout flares 57 lipid lowering medications 57 ejection fraction 57 onset atrial fibrillation 57 URTI 57 RLS symptoms 57 virologic suppression 57 nonoperative 57 cinacalcet 57 lactate dehydrogenase LDH 57 MADRS 57 urine cytology 57 bronchopulmonary dysplasia 57 chest radiographs 57 proliferative retinopathy 57 transaminases 57 SVR# 57 patients evaluable 57 virologic 57 TURBT 57 nontraumatic 57 DMARDs 57 ancrod 57 lymphocyte counts 57 Charlson comorbidity index 57 decompensated heart failure 57 lipid lowering therapy 57 macular thickness 57 nighttime awakenings 57 lanthanum carbonate 57 dose Iluvien 57 liver enzymes ALT 57 systolic function 57 budesonide pMDI 57 adrenalectomy 57 peginterferon 57 CK MB 57 juvenile idiopathic arthritis 57 malignant neoplasm 57 SGPT 57 NATRECOR ® 57 virologic breakthrough 57 Heavy menstrual bleeding 57 nmol L. 57 vertebral fracture 57 PUFA intake 57 vasopressor 57 postop 57 nonsignificant difference 57 symptomatic VTE 57 graft dysfunction 57 ejection fraction EF 57 residual platelet reactivity 57 androgen suppression 57 CIN2 + 57 μg dose 57 PCa 57 COPAXONE ® 57 #mg/day [002] 57 ventricular enlargement 57 serum sodium levels 57 serum estradiol 57 oral prednisone 57 mg TID 57 inhaled budesonide 57 urine NGAL 57 seropositive patients 57 hypogonadal 57 PaO 2 57 FOLFIRINOX 57 hematologic parameters 57 highest tertile 57 State Examination MMSE 57 postinjury 57 interrater reliability 57 preserved ejection fraction 57 mCRPC 57 QoL 57 #OHD levels 57 relapsed AML 57 fasting plasma glucose 57 reinfarction 57 Infusion Reactions Severe 57 parathyroidectomy 57 alicaforsen enema 57 tPSA 57 permanently discontinue Vectibix 57 pimecrolimus cream 57 intact parathyroid hormone 57 severe neutropenia 57 sustained ventricular tachycardia 57 undetectable viral 57 A1C levels 57 methacholine challenge 57 BLLs 57 hepatectomy 57 Logistic regression analysis 57 Fibromyalgia Impact Questionnaire 57 abdominal pain abdominal discomfort 57 noninferiority 57 rFSH 57 solifenacin 57 nadolol 57 severe rotavirus gastroenteritis 57 QALE 57 HBV DNA levels 57 hypopneas 57 point Likert scale 57 glycemia 57 cells mcL 57 LV ejection fraction 57 Rate ORR 57 Renal Cell Carcinoma RCC 57 hepatic resection 57 postdose 57 varices 57 aripiprazole 57 conduction velocity 57 gastric pH 57 ALSFRS R 57 virologic responses 57 conditional logistic regression 57 nonsignificant 57 reintubation 57 biventricular repair 57 ropivacaine 57 aminotransferase ALT 57 undetectable HCV RNA 57 COMBIVIR 57 somatostatin analog 57 vitreous haze 57 salmeterol HFA MDI 57 treat NNT 57 revascularization procedures 57 triglyceride concentration 57 #q# deletion syndrome 57 glycosylated hemoglobin levels 57 placebo PBO 57 antithrombotic therapy 57 non valvular atrial 57 cabazitaxel